Sharemaestro company-news research for Roivant Sciences Ltd (ROIV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ROIV news and sentiment
Roivant Sciences Ltd
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
45 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone65/100
→
Published 30-day score52/100
Latest source headline
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
Benzinga · 05 Oct 2026 11:04
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
45 current stories are mapped specifically to ROIV.
The score uses 10 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.150.
Confidence is 22/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
100%/100
Company news45 company stories
90/100
Story agreement10/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.15 after freshness weightingSource breadth100
10 independent publishersCompany relevance100
share tied directly to this companyFreshness22
recency-weighted evidenceAgreement90
how closely stories agreePublisher mix56
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202655USD 35.72-0.2%
25 Sep 202656USD 35.8-10.0%
18 Sep 202661USD 39.77-2.6%
11 Sep 202663USD 40.82+16.9%
04 Sep 202659USD 34.93+0.6%
28 Aug 202659USD 34.71-4.4%
21 Aug 202653USD 36.3+0.3%
14 Aug 202651USD 36.2-0.4%
Provisional evidence
News subjects
What is shaping the score
Market update4828 stories · 62%
Earnings5410 stories · 22%
Analyst action723 stories · 7%
Regulatory and legal583 stories · 7%
Guidance501 stories · 2%
Source mix
Where the evidence comes from
Stock Titan4614 stories · 31%
Stocktwits793 stories · 7%
Insider Monkey553 stories · 7%
Investing.com Nigeria503 stories · 7%
Moomoo642 stories · 4%
Benzinga502 stories · 4%
Yahoo! Finance Canada502 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences25Financial Markets18Finance11Earnings11Clinical Trials5Biotech4Pharma2Fda Approval2Revenue Growth1Pulmonary Disease1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
28 Jul50 neutral09 Oct 06:16
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 09 Oct 06:16 | 52 | -1 | 21/100 (-3) | 46 (-14) | Provisional |
| 05 Oct 23:59 | 53 | -1 | 24/100 (-4) | 60 (-2) | Provisional |
| 03 Oct 23:59 | 54 | -1 | 28/100 (+2) | 62 (+6) | Provisional |
| 02 Oct 23:59 | 55 | -1 | 26/100 (-2) | 56 (+1) | Provisional |
| 01 Oct 23:59 | 56 | +0 | 28/100 (-1) | 55 (+1) | Provisional |
| 30 Sep 23:59 | 56 | -1 | 29/100 (-2) | 54 (0) | Provisional |
| 29 Sep 23:59 | 57 | +0 | 31/100 (-2) | 54 (+1) | Provisional |
| 28 Sep 23:59 | 57 | +0 | 33/100 (+1) | 53 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 45 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
0.0%64.7%
Earnings3 stories
0.0%13.4%
Market update7 stories
11.2%0.2%
Analyst action3 stories
0.0%10.5%
Each side uses the same scale: 0–64.7% of the retained directional evidence.
Where the influence comes from
64.7%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
Roivant Sciences held its Q1 2027 earnings call, discussing a quiet quarter but anticipating a busy second half with the expected launch of brepocitinib by September. The company highlighted progress in its pipeline, including the initiation of a Phase 3 study for brepocitinib in cutaneou…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences held its Q1 2027 earnings call, discussing a quiet quarter but anticipating a busy second half with the expected launch of brepocitinib by September. The company highlighted progress in its pipeline, including the initiation of a Phase 3 study for brepocitinib in cutaneous sarcoidosis and ongoing enrollment for lichen planopilaris. Financially, Roivant reported $950 million from a Moderna settlement, approximately $200 million in R&D expenses, and nearly $100 million in non-GAAP G&A expenses, with a cash position of just under $4 billion.
- Published
- 05 Oct 2026 11:04
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife SciencesFinance
—Unscored
Market updateNot used in direction
How (ROIV) Movements Inform Risk Allocation Models
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) stock, highlighting divergent sentiment across time horizons and a mid-channel oscillation pattern. It presents an exceptional 28.8:1 risk-reward setup, targeting an 8.2% gain versus 0.3% risk. The analysis includes AI-generated t…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) stock, highlighting divergent sentiment across time horizons and a mid-channel oscillation pattern. It presents an exceptional 28.8:1 risk-reward setup, targeting an 8.2% gain versus 0.3% risk. The analysis includes AI-generated trading strategies for different risk profiles, offering position trading, momentum breakout, and risk hedging approaches.
- Published
- 03 Oct 2026 17:28
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme.
Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, had 46,879 common shares withheld on September 30, 2026, to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs). The shares were valued at $36.57 each, amounting to appr…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, had 46,879 common shares withheld on September 30, 2026, to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs). The shares were valued at $36.57 each, amounting to approximately $1.71 million. Following this transaction, Sukhatme directly holds 18,583,860 common shares in the company.
- Published
- 03 Oct 2026 12:34
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
40/100 tone
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), exercised options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares at a weighted average price of $36.62 per share on September 30, 2026. These transactions were executed under a …
11% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), exercised options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares at a weighted average price of $36.62 per share on September 30, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in March 2025. Following these sales, Venker's direct stock-option position was 3,644,834 shares and 1,599,154 common shares.
- Published
- 03 Oct 2026 12:34
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 11% of directional evidence · 5.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Roivant Sciences(ROIV.US) Officer Sells US$7.32 Million in Common Stock
An officer at Roivant Sciences (ROIV.US) recently sold a significant amount of common stock, totaling US$7.32 million. This transaction provides insight into insider activity at the company.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
An officer at Roivant Sciences (ROIV.US) recently sold a significant amount of common stock, totaling US$7.32 million. This transaction provides insight into insider activity at the company.
- Published
- 03 Oct 2026 05:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Roivant Sciences Ltd. For: 2 October By Investing.com
This article reports on a Form 4 filing for Roivant Sciences Ltd. related to activity on October 2nd. The content is brief and primarily serves as a notification of the filing, with no further details provided within the article itself. It includes the stock symbol ROIV.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article reports on a Form 4 filing for Roivant Sciences Ltd. related to activity on October 2nd. The content is brief and primarily serves as a notification of the filing, with no further details provided within the article itself. It includes the stock symbol ROIV.
- Published
- 03 Oct 2026 03:02
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
—Unscored
Market updateNot used in direction
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares.
Frank Torti, President and Vant Chair of Roivant Sciences (ROIV), acquired 40,309 common shares on September 30, 2026. This acquisition was a result of the net settlement of previously granted Restricted Stock Units (RSUs) to cover tax withholding obligations. Following this transaction, …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Frank Torti, President and Vant Chair of Roivant Sciences (ROIV), acquired 40,309 common shares on September 30, 2026. This acquisition was a result of the net settlement of previously granted Restricted Stock Units (RSUs) to cover tax withholding obligations. Following this transaction, Torti's reported holdings in Roivant Sciences totaled 13,495,893 common shares, with the acquired shares valued at $36.57 each.
- Published
- 03 Oct 2026 01:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes.
Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 common shares on September 30, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). The shares were valued at $36.57 each. Following this transaction, Gline direc…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 common shares on September 30, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). The shares were valued at $36.57 each. Following this transaction, Gline directly holds 16,583,774 common shares in the company.
- Published
- 02 Oct 2026 23:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 39.09%. An investment of $1000 in ROIV five years ago would now be worth $4,366.54, highlighting the power of compounded returns. The company currently has a ma…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 39.09%. An investment of $1000 in ROIV five years ago would now be worth $4,366.54, highlighting the power of compounded returns. The company currently has a market capitalization of $25.77 billion.
- Published
- 01 Oct 2026 22:56
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com
This article reports on a Form 144 filing by Roivant Sciences Ltd. on October 1st. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides the date of the filing and mentions Roivant Sciences Ltd. (ROIV) with a slight s…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article reports on a Form 144 filing by Roivant Sciences Ltd. on October 1st. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides the date of the filing and mentions Roivant Sciences Ltd. (ROIV) with a slight stock percentage change.
- Published
- 01 Oct 2026 18:26
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale.
Roivant Sciences Ltd. officer Eric Venker has proposed selling 200,000 common shares worth $7.32 million through Rockefeller Financial LLC on September 30, 2026, under a Rule 10b5-1 trading plan. This proposed sale follows previous sales in July and August 2026, including a significant sa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Ltd. officer Eric Venker has proposed selling 200,000 common shares worth $7.32 million through Rockefeller Financial LLC on September 30, 2026, under a Rule 10b5-1 trading plan. This proposed sale follows previous sales in July and August 2026, including a significant sale of 200,000 shares for $7.15 million on August 28, 2026. The filing provides details on the acquisition of the securities through an options exercise from April 20, 2022.
- Published
- 30 Sep 2026 20:02
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 16:33
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
GuidanceNot used in direction
Roivant Sciences Ltd (ROIV) Stock Price Target & Forecast
Analysts have provided a price target and forecast for Roivant Sciences Ltd (ROIV). Based on 12 analysts, the average target price is $46.482, representing a potential upside of 29.84%. The stock currently has a "Buy" trend with 6 Buy ratings and 1 Hold rating in the last month, and finan…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Analysts have provided a price target and forecast for Roivant Sciences Ltd (ROIV). Based on 12 analysts, the average target price is $46.482, representing a potential upside of 29.84%. The stock currently has a "Buy" trend with 6 Buy ratings and 1 Hold rating in the last month, and financial forecasts for EPS and revenue are also provided.
- Published
- 29 Sep 2026 09:31
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
67/100 tone
Roivant Sciences (ROIV) saw a 3.7% increase in its stock price, attributed to continued investor enthusiasm following positive Phase 2 clinical data for mosliciguat, recent FDA approval for LISRAYA, and bullish analyst sentiment. Although there was no new company-specific announcement, th…
64.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Roivant Sciences (ROIV) saw a 3.7% increase in its stock price, attributed to continued investor enthusiasm following positive Phase 2 clinical data for mosliciguat, recent FDA approval for LISRAYA, and bullish analyst sentiment. Although there was no new company-specific announcement, the gain likely reflects sustained momentum and positioning for upcoming pipeline milestones expected in the second half of 2026. Insider selling activity has been significant over the past six months, while hedge funds show mixed but substantial position changes.
- Published
- 28 Sep 2026 17:36
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 64.7% of directional evidence · 10.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences is preparing for the launch of LISRAYA, a newly approved drug for dermatomyositis, while also advancing key pipeline programs. CEO Matthew Gline highlighted upcoming clinical data for brepocitinib (LISRAYA) in non-infectious uveitis and Immunovant’s IMVT-1402 in rheumatoi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences is preparing for the launch of LISRAYA, a newly approved drug for dermatomyositis, while also advancing key pipeline programs. CEO Matthew Gline highlighted upcoming clinical data for brepocitinib (LISRAYA) in non-infectious uveitis and Immunovant’s IMVT-1402 in rheumatoid arthritis, cutaneous lupus erythematosus, and Graves’ disease. Additionally, the company is expanding its pulmonary hypertension program with mosliciguat, following positive Phase II results.
- Published
- 28 Sep 2026 07:49
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Form 4 Roivant Sciences Ltd. For: 28 September By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4, for Roivant Sciences Ltd., dated September 28. It indicates insider transaction activity for the company. The content primarily serves as a placeholder for the filing information, with little additional …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article from Investing.com is a regulatory filing update, specifically a Form 4, for Roivant Sciences Ltd., dated September 28. It indicates insider transaction activity for the company. The content primarily serves as a placeholder for the filing information, with little additional detail provided within the article itself.
- Published
- 28 Sep 2026 05:58
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Form 4 Roivant Sciences Ltd. For: 27 September By Investing.com
This article announces the filing of a Form 4 for Roivant Sciences Ltd. on September 27. It contains minimal actual content beyond the title, serving as a placeholder for the regulatory filing information. The piece includes various financial market data, news headlines, and stock perform…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article announces the filing of a Form 4 for Roivant Sciences Ltd. on September 27. It contains minimal actual content beyond the title, serving as a placeholder for the regulatory filing information. The piece includes various financial market data, news headlines, and stock performance figures, typical of an Investing.com page.
- Published
- 28 Sep 2026 02:41
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
74/100 tone
Bernstein has initiated coverage on Roivant Sciences (ROIV.US) with a Buy rating. The firm has set a price target of $41 for the company's stock. This indicates a positive outlook from Bernstein regarding Roivant Sciences' future performance.
7.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Bernstein has initiated coverage on Roivant Sciences (ROIV.US) with a Buy rating. The firm has set a price target of $41 for the company's stock. This indicates a positive outlook from Bernstein regarding Roivant Sciences' future performance.
- Published
- 26 Sep 2026 03:21
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 7.9% of directional evidence · 13.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
Roivant Sciences Ltd. (NASDAQ: ROIV) saw its shares jump after reporting positive Phase 2 results for mosliciguat, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug met both primary and secondary endpoints, leading Roivant to initiate a Ph…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Ltd. (NASDAQ: ROIV) saw its shares jump after reporting positive Phase 2 results for mosliciguat, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug met both primary and secondary endpoints, leading Roivant to initiate a Phase 3 study. This development positions mosliciguat as another significant late-stage asset for the company, following the recent FDA approval of Lisraya.
- Published
- 25 Sep 2026 09:55
- News subject
- Earnings
- Why this score
- Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Clinical TrialsEarningsFda ApprovalLife SciencesPharma
—Unscored
Market updateNot used in direction
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes
Roivant Sciences Ltd.'s Chief Accounting Officer, Jennifer Humes, had 3,880 common shares withheld to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs). This transaction, which occurred on September 20, 2026, at a price of $39.77 per share, leaves her with a …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Ltd.'s Chief Accounting Officer, Jennifer Humes, had 3,880 common shares withheld to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs). This transaction, which occurred on September 20, 2026, at a price of $39.77 per share, leaves her with a direct holding of 106,419 common shares. The disposition was a "net settlement" and not part of a Rule 10b5-1 trading plan.
- Published
- 23 Sep 2026 23:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Roivant Sciences Ltd. For: 22 September By Investing.com
This Investing.com article reports on a Form 4 filing for Roivant Sciences Ltd. related to September 22. It mentions the company's stock symbol ROIV and notes that no comments have been made on the filing. The article appears to be a brief financial news update providing minimal detail be…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This Investing.com article reports on a Form 4 filing for Roivant Sciences Ltd. related to September 22. It mentions the company's stock symbol ROIV and notes that no comments have been made on the filing. The article appears to be a brief financial news update providing minimal detail beyond the filing's existence.
- Published
- 23 Sep 2026 20:24
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
43/100 tone
0.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 12:12
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 0.2% of directional evidence · 15.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 11:47
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Roivant Sciences Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consi
- Published
- 23 Sep 2026 11:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.8d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Autoimmune DiseasesBiotechClinical Trials
—Unscored
EarningsNot used in direction
Why Roivant Sciences (ROIV) Is Back In The Spotlight
Roivant Sciences (ROIV) has garnered attention due to positive Phase 2 PHocus results for mosliciguat, showing a significant reduction in pulmonary vascular resistance. Despite this, the stock trades below analyst targets, and a narrative suggests it is overvalued, citing risks related to…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences (ROIV) has garnered attention due to positive Phase 2 PHocus results for mosliciguat, showing a significant reduction in pulmonary vascular resistance. Despite this, the stock trades below analyst targets, and a narrative suggests it is overvalued, citing risks related to IP litigation, competition in the autoimmune space, monetization strategy, and a conglomerate discount. The article highlights both the potential upsides from clinical success and the market's current cautious valuation of the company.
- Published
- 23 Sep 2026 09:55
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding
Roivant Sciences' CFO, Richard Pulik, had 2,129 common shares withheld on September 20, 2026, to cover tax withholding obligations from vested Restricted Stock Units (RSUs). This transaction was a net share settlement, not an open-market sale, and resulted in Pulik directly holding 269,68…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roivant Sciences' CFO, Richard Pulik, had 2,129 common shares withheld on September 20, 2026, to cover tax withholding obligations from vested Restricted Stock Units (RSUs). This transaction was a net share settlement, not an open-market sale, and resulted in Pulik directly holding 269,681 common shares. The shares were valued at $39.77 each for tax purposes.
- Published
- 23 Sep 2026 09:55
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
EarningsNot used in direction
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History
This article provides comprehensive financial data for Roivant Sciences Ltd. (ROIV), including its current stock price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus, outlining its clinical product candidates and deli…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides comprehensive financial data for Roivant Sciences Ltd. (ROIV), including its current stock price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus, outlining its clinical product candidates and delivery platforms. The report also compares ROIV's performance against the S&P 500 and presents earnings trends and analyst price targets.
- Published
- 23 Sep 2026 07:38
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
56/100 tone
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a …
1.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that time. Stifel argued that Roivant offers multiple late-stage opportunities across specialty autoimmune and pulmonary diseases. The firm projects around $9 billion in ownership-adjusted sales for Roivant by 2037. Can Roivant turn its multi-asset strategy into long-
- Published
- 22 Sep 2026 10:27
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 1.3% of directional evidence · 16.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsFda ApprovalPrice TargetRevenue Growth
57/100 tone
Roivant Sciences Ltd. (ROIV) is a UK-based biopharmaceutical company with a market capitalization of $28.73 billion, focusing on innovative medicines. Despite currently being unprofitable with a negative P/E ratio, analysts project a 20% upside due to its strong product pipeline, includin…
0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Roivant Sciences Ltd. (ROIV) is a UK-based biopharmaceutical company with a market capitalization of $28.73 billion, focusing on innovative medicines. Despite currently being unprofitable with a negative P/E ratio, analysts project a 20% upside due to its strong product pipeline, including IMVT-1402 and mosliciguat, and bullish technical indicators. The company's significant investment in R&D and strategic focus on unmet medical needs position it as a compelling, albeit risky, growth opportunity in the biotech sector.
- Published
- 21 Sep 2026 09:55
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.1% of directional evidence · 17.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
59/100 tone
Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted …
6.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted the PHocus findings at recent scientific conference presentations focused on pulmonary hypertension and interstitial lung disease. There is more to Roivant than the PHocus mosliciguat data investors are hearing about today. Our analysis turns up 2 other big wins for Roivant Sciences as well. For a wider view o
- Published
- 18 Sep 2026 11:15
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 6.1% of directional evidence · 20.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsHealthcarePulmonary Disease
Earlier company news
ROIV news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 133 older ROIV headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ROIV, but the headline and available text are not mainly about Roivant Sciences Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ROIV sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.